Get the Stockscreener App
5.72
0.00%
0.00
After Hours:
5.72
Nevro Corp stock is traded at $5.72, with a volume of 2.13M.
It is up +0.00% in the last 24 hours and up +73.86% over the past month.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
See More
Previous Close:
$5.72
Open:
$5.73
24h Volume:
2.13M
Relative Volume:
2.50
Market Cap:
$214.34M
Revenue:
$425.17M
Net Income/Loss:
$-92.21M
P/E Ratio:
-2.2257
EPS:
-2.57
Net Cash Flow:
$-67.42M
1W Performance:
+11.50%
1M Performance:
+73.86%
6M Performance:
-4.83%
1Y Performance:
-66.65%
1-Day Range:
$5.71
$5.74
1-Week Range:
$5.00
$5.80
52-Week Range:
$3.165
$17.75
Nevro Corp Stock (NVRO) Company Profile
Name
Nevro Corp
Sector
Industry
Phone
650-251-0005
Address
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Compare NVRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
5.72 | 214.34M | 425.17M | -92.21M | -67.42M | -2.57 |
|
ABT
Abbott Laboratories
|
131.44 | 227.98B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.98 | 156.20B | 16.75B | 1.85B | 1.89B | 1.25 |
|
SYK
Stryker Corp
|
390.48 | 148.86B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.20 | 116.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.91 | 41.82B | 6.60B | 4.16B | 490.10M | 6.93 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-07-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-03-24 | Initiated | Wells Fargo | Equal Weight |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-09-24 | Upgrade | Citigroup | Sell → Neutral |
| Aug-08-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Aug-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-07-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-07-24 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-22-24 | Downgrade | Citigroup | Neutral → Sell |
| Feb-22-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-21-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| May-31-23 | Initiated | RBC Capital Mkts | Outperform |
| May-15-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-14-23 | Initiated | Mizuho | Neutral |
| Jan-17-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Downgrade | Piper Sandler | Neutral → Underweight |
| Dec-20-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-12-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Apr-13-22 | Resumed | Truist | Hold |
| Apr-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-09-21 | Downgrade | Truist | Buy → Hold |
| Aug-05-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-05-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-05-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-09-21 | Downgrade | Redburn | Buy → Neutral |
| Jul-06-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-02-21 | Initiated | Piper Sandler | Overweight |
| Oct-23-20 | Initiated | Guggenheim | Buy |
| Sep-02-20 | Initiated | Robert W. Baird | Outperform |
| Jun-08-20 | Upgrade | UBS | Sell → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-22-19 | Initiated | Oppenheimer | Perform |
| Mar-20-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-20-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-28-18 | Initiated | UBS | Sell |
| Nov-07-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-06-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-06-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-19-18 | Downgrade | Goldman | Neutral → Sell |
| Jul-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-08-18 | Reiterated | Canaccord Genuity | Buy |
| May-08-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-08-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
View All
Nevro Corp Stock (NVRO) Latest News
Nevro (NYSE:NVRO) Price Target Raised to $5.85 - MarketBeat
Nevro (NYSE:NVRO) Upgraded by Piper Sandler to "Overweight" Rating - MarketBeat
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain? - Yahoo Finance
Globus Medical strengthens SCS market position with $250m Nevro deal - Yahoo Finance
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp.NVRO - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders - Marketscreener.com
Jefferies raises Nevro stock rating, boosts price target to $5.85 - MSN
Stifel maintains GMED buy rating, $92 target amid NVRO buyout - MSN
Jefferies Upgrades Nevro to Hold From Underperform, Adjusts Price Target to $5.85 From $4.50 - Marketscreener.com
Jefferies raises Nevro stock rating, boosts price target to $5.85 By Investing.com - Investing.com Australia
Nevro (NYSE:NVRO) Stock Rating Upgraded by Jefferies Financial Group - MarketBeat
Needham maintains hold on Globus Medical stock post-acquisition - MSN
Jefferies Upgrades Nevro Corp (NVRO) to Hold - StreetInsider.com
Globus Medical to Acquire Nevro Corp. in Strategic $250 Million Deal - MSN
Jefferies maintains Buy on Globus Medical, target at $105 - MSN
Globus Medical Enters into Merger Agreement with Nevro Corp. - Armenian Reporter
Globus Medical to acquire Nevro for $5.85 per share - MSN
Piper Sandler Upgrades Nevro (NVRO) - Nasdaq
Demystifying Nevro: Insights From 11 Analyst Reviews - Benzinga
Nevro (NVRO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Nevro upgraded to Neutral from Underweight at Piper Sandler - MSN
Piper Sandler Upgrades Nevro to Neutral From Underweight, Adjusts Price Target to $5.85 From $6 - Marketscreener.com
Globus Medical, Inc. entered into a definitive agreement to acquire Nevro Corp. for approximately $250 million. - Marketscreener.com
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Altus Power, Amazon, Nevro - TradingView
Piper Sandler raises Nevro stock to Neutral, cuts target to $5.85 - MSN
Globus Medical to acquire Nevro for $250 million By Investing.com - Investing.com Nigeria
Piper Sandler Upgrades Nevro Corp (NVRO) to Neutral - StreetInsider.com
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Nevro Corp.NVRO - The Malaysian Reserve
Globus Medical to Acquire Nevro for $250M - MD+DI
Items Tagged with 'joint fusion' - BioWorld Online
Globus Medical buying chronic pain company Nevro for $250M - BioWorld Online
Latham & Watkins Advises Nevro in Acquisition by Globus Medical - Latham & Watkins LLP
BTIG maintains $91 target on Globus Medical stock post-acquisition - MSN
Globus Medical Announces Acquisition of Nevro Corp - TipRanks
Canaccord maintains Buy rating, $101 target on Globus Medical stock - MSN
Nevro Corp Announces Merger Agreement with Globus Medical - TipRanks
Globus Medical Buys Device Maker Nevro In $250M Deal - Law360
Globus Medical to acquire Nevro for $250 million - MSN
Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio - Yahoo Finance
Globus Medical to buy California life sciences firm for $250M - The Business Journals
Globus Medical To Acquire Nevro For $250 Mln - Nasdaq
Nevro Corp (NVRO) PT Raised to $5.85 at Canaccord Genuity - StreetInsider.com
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders - Business Wire
Globus Medical to acquire Nevro for $250M - Mass Device
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Globus Medical to Acquire Nevro -February 06, 2025 at 09:58 am EST - Marketscreener.com
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients - GlobeNewswire
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients - Benzinga
Major Medical Device Acquisition: Globus Medical Takes Over Nevro in Strategic $250M Pain Tech Deal - StockTitan
Nevro (NVRO) Cash-to-Debt : 1.12 (As of Sep. 2024) - GuruFocus.com
Nevro Corp Stock (NVRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):